Page last updated: 2024-10-27

fluoxetine and Aging

fluoxetine has been researched along with Aging in 73 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
" The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine."9.17L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( Bersani, FS; Bersani, G; Colletti, C; Denaro, A; Koverech, A; Liberati, D; Meco, G; Nicolai, R, 2013)
"The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder."9.11Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( Cheng, J; Devanand, DP; Nobler, MS; Pelton, GH; Roose, SP; Sackeim, HA; Turret, N, 2005)
" Aging decreases expression of mRNA for vasoactive intestinal peptide (VIP), a key neuropeptide for rhythm generation and photic phase shifts, and increases expression of serotonin transporters and 5-HT(1B) receptors, whose activation inhibits these phase shifts."7.76The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors. ( Duncan, MJ; Franklin, KM; Hester, JM; Hopper, JA, 2010)
"Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery."7.73Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006)
"Male F344BNF1 hybrid rats (F1 crosses between female Fischer 344 and male Brown Norway rats) aged 3 or 24 months were treated with vehicle (1 ml water/kg, IP) or fluoxetine (10 mg/kg, IP) once a day for 1 day or 27 consecutive days; body weights were recorded daily."7.68Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats. ( Alper, RH, 1992)
" In animal experiments, chronic administration of fluoxetine induces increased excitability of mature granule cells (GCs), enhancing axonal and dendritic reorganization, as well as promoting neurogenesis or angiogenesis in the dentate gurus (DG), but the effect of fluoxetine in the subventricular zone (SVZ) remains controversial."6.55Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. ( Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017)
"Fluoxetine treatment of old mice further increased hippocampal S100B, suggesting that aging does not interfere with fluoxetine's action on hippocampal S100B."5.32Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. ( Akhisaroglu, E; Akhisaroglu, M; Manev, H; Manev, R; Uz, T, 2003)
"The pharmacological and physiological effects of chronic administration of the selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor (SSRI) fluoxetine and the dual 5-HT/norepinephrine (NE) reuptake inhibitor duloxetine were compared on 5-HT-mediated electrophysiological responses recorded in the hippocampus of young (3-5 months) and old (17-20 months) female Fischer 344 rats."5.30Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus. ( Lakoski, JM; Smith, JE, 1998)
" The aim of the study is to verify whether LAC can have an antidepressant action in a population of elderly patients with dysthymic disorder in comparison with a traditional antidepressant such as fluoxetine."5.17L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. ( Bersani, FS; Bersani, G; Colletti, C; Denaro, A; Koverech, A; Liberati, D; Meco, G; Nicolai, R, 2013)
"The authors compared the efficacy and side effects of fluoxetine and placebo in elderly outpatients with dysthymic disorder."5.11Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. ( Cheng, J; Devanand, DP; Nobler, MS; Pelton, GH; Roose, SP; Sackeim, HA; Turret, N, 2005)
"After 1 month treatment, vortioxetine improved visuospatial memory and reduced depression-like behavior."3.85Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice. ( Gulinello, M; Li, Y; Sanchez, C, 2017)
" Here, we investigated the role of aging in the behavioral effects of the antidepressants, desipramine (DMI) (5, 10, and 20 mg/kg) and fluoxetine (FLX) (5, 10, and 20 mg/kg) in young adults (3-5 months), middle-aged (MA, 12-15 months), and senescent (SE, 23-25 months) male rats in the forced-swim test."3.83Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test. ( Fernández-Guasti, A; Martínez-Mota, L; Olivares-Nazario, M, 2016)
" Aging decreases expression of mRNA for vasoactive intestinal peptide (VIP), a key neuropeptide for rhythm generation and photic phase shifts, and increases expression of serotonin transporters and 5-HT(1B) receptors, whose activation inhibits these phase shifts."3.76The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors. ( Duncan, MJ; Franklin, KM; Hester, JM; Hopper, JA, 2010)
"Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery."3.73Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006)
"Male F344BNF1 hybrid rats (F1 crosses between female Fischer 344 and male Brown Norway rats) aged 3 or 24 months were treated with vehicle (1 ml water/kg, IP) or fluoxetine (10 mg/kg, IP) once a day for 1 day or 27 consecutive days; body weights were recorded daily."3.68Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats. ( Alper, RH, 1992)
" In animal experiments, chronic administration of fluoxetine induces increased excitability of mature granule cells (GCs), enhancing axonal and dendritic reorganization, as well as promoting neurogenesis or angiogenesis in the dentate gurus (DG), but the effect of fluoxetine in the subventricular zone (SVZ) remains controversial."2.55Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. ( Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017)
"Fluoxetine has a nonlinear pharmacokinetic profile."2.39Clinical pharmacokinetics of fluoxetine. ( Altamura, AC; Moro, AR; Percudani, M, 1994)
"The body weight was determined, and behavior tests, including sucrose preference test, forced swimming test and open field test were performed."1.56Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model. ( Wang, G; Wang, H; Xiao, L, 2020)
"Fluoxetine is an antidepressant, which exerts a powerful neurogenic effect on dentate gyrus progenitor cells, but is ineffective on stem cells."1.48Fluoxetine or Sox2 reactivate proliferation-defective stem and progenitor cells of the adult and aged dentate gyrus. ( Caruso, C; Ceccarelli, M; Coccurello, R; Costanzi, M; D'Andrea, G; Giacovazzo, G; Micheli, L; Tirone, F, 2018)
"Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor known for its effects modifying aggressiveness, personality traits, and anxiety-like behaviors."1.46Acute fluoxetine treatment increases aggressiveness in juvenile matrinxã (Brycon amazonicus). ( Barbosa Júnior, A; Serra, M; Urbinati, EC; Wolkers, CPB, 2017)
"Fluoxetine treatment in adulthood evokes antidepressant and anxiolytic responses."1.40Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. ( Chachra, P; Desouza, LA; Kennedy, P; Nestler, EJ; Pena, CJ; Sarkar, A; Vaidya, VA, 2014)
"Depression is recognized as a predictor of increased cardiac morbidity and mortality."1.37Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging. ( Belzung, C; Camus, V; d'Audiffret, A; Isingrini, E, 2011)
"Fluoxetine has been reported to decrease the number of "mature" calbindin-positive cells in the dentate gyrus; we found this still occurred on the side of a CA3 lesion."1.37Novel control by the CA3 region of the hippocampus on neurogenesis in the dentate gyrus of the adult rat. ( Herbert, J; Liu, JX; Pinnock, SB, 2011)
" Dam dosing was adjusted to reflect the 50th and 85th percentiles of serum concentrations observed in pregnant women."1.37Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. ( Bourke, CH; Capello, CF; Nemeroff, A; Newport, DJ; Owens, MJ; Ritchie, JC; Stowe, ZN, 2011)
"The fluoxetine treatment induced active somatic membrane properties resembling immature granule cells and markedly reduced synaptic facilitation that characterizes the mature dentate-to-CA3 signal transmission."1.36Reversal of hippocampal neuronal maturation by serotonergic antidepressants. ( Haneda, E; Ikeda, Y; Kobayashi, K; Miyakawa, T; Sakai, A; Suzuki, H; Yamasaki, N, 2010)
"Fluoxetine also did not increase forced swim struggle behavior in juvenile mice of all strains, but was effective in increasing struggle in adults."1.35Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains. ( Baker, KB; Davis, KW; Gerhardt, B; Lanthorn, TH; Malbari, MM; Mason, SS; Pogorelov, VM; Ritter, R; Savelieva, KV; Wray, SP, 2009)
"Fluoxetine treatment increased GR mRNA in the hippocampus of young rats (24 and 46% increase in DG and CA3, respectively, P<0."1.31The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. ( Hibberd, C; Noble, J; Seckl, JR; Yau, JL, 2002)
"The pharmacological and physiological effects of chronic administration of the selective serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibitor (SSRI) fluoxetine and the dual 5-HT/norepinephrine (NE) reuptake inhibitor duloxetine were compared on 5-HT-mediated electrophysiological responses recorded in the hippocampus of young (3-5 months) and old (17-20 months) female Fischer 344 rats."1.30Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus. ( Lakoski, JM; Smith, JE, 1998)
"Fluoxetine-treated animals on the other hand, showed a great amplification of plasticity with a conspicuous sprouting of the uncrossed retinal axons into denervated areas."1.30Fluoxetine-induced plasticity in the rodent visual system. ( Amaral, AR; Bastos, EF; Marcelino, JL; Serfaty, CA, 1999)
"Fluoxetine was administered via the drinking water (5 mg/kg/day) for a period of two weeks to very young (day 25) and somewhat older (day 50) rats."1.30Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. ( Bagli, M; Huether, G; Moll, GH; Rothenberger, A; Rüther, E; Wegerer, V, 1999)
"Fluoxetine treatment resulted in a nonsignificant increase in nociceptive response at 30 min posttreatment which returned to the baseline by 1 h."1.29Serotonin modulation of pain responsiveness in the aged rat. ( Akunne, HC; Soliman, KF, 1994)
"[3H]Nisoxetine ([3H]NIS) was used to measure uptake sites for norepinephrine (NE) in the locus coeruleus (LC) of humans."1.28Effect of age on [3H]nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans. ( Ordway, GA; Tejani-Butt, SM, 1992)

Research

Studies (73)

TimeframeStudies, this research(%)All Research%
pre-19903 (4.11)18.7374
1990's11 (15.07)18.2507
2000's25 (34.25)29.6817
2010's30 (41.10)24.3611
2020's4 (5.48)2.80

Authors

AuthorsStudies
Petrascheck, M2
Ye, X1
Buck, LB1
Liang, Z1
Jia, Y1
Zhao, L1
Zhu, R1
He, X1
Tong, B1
Yang, F1
Hao, L1
Cui, P1
Yuan, J1
Tunc-Ozcan, E1
Brooker, SM1
Bonds, JA1
Tsai, YH1
Rawat, R1
McGuire, TL1
Peng, CY1
Kessler, JA1
Wang, H2
Xiao, L1
Wang, G1
Iñiguez, SD2
Flores-Ramirez, FJ1
Themann, A1
Lira, O1
Duda, W1
Kubera, M2
Kreiner, G1
Curzytek, K1
Detka, J1
Głombik, K1
Ślusarczyk, J1
Basta-Kaim, A2
Budziszewska, B2
Lasoń, W1
Regulska, M1
Leśkiewicz, M1
Roman, A1
Zelek-Molik, A1
Nalepa, I1
Kiryanova, V1
Meunier, SJ1
Dyck, RH1
Connor, DA1
Gould, TJ1
Sun, Y1
Sun, X1
Qu, H1
Zhao, S1
Xiao, T1
Zhao, C1
Kalogeraki, E1
Pielecka-Fortuna, J1
Löwel, S1
Masrour, FF1
Peeri, M1
Azarbayjani, MA1
Hosseini, MJ1
Eavri, R1
Shepherd, J1
Welsh, CA1
Flanders, GH1
Bear, MF1
Nedivi, E1
Micheli, L1
Ceccarelli, M1
D'Andrea, G1
Costanzi, M1
Giacovazzo, G1
Coccurello, R1
Caruso, C1
Tirone, F1
Bersani, G1
Meco, G1
Denaro, A1
Liberati, D1
Colletti, C1
Nicolai, R1
Bersani, FS1
Koverech, A1
Francis-Oliveira, J1
Ponte, B1
Barbosa, AP1
Veríssimo, LF1
Gomes, MV1
Pelosi, GG1
Britto, LR1
Moreira, EG1
Darcy, MJ1
Trouche, S1
Jin, SX1
Feig, LA1
Ohira, K2
Takeuchi, R1
Iwanaga, T1
Miyakawa, T3
Sarkar, A1
Chachra, P1
Kennedy, P1
Pena, CJ1
Desouza, LA1
Nestler, EJ1
Vaidya, VA1
Bourke, CH2
Glasper, ER1
Neigh, GN1
Steiner, H1
Warren, BL2
Van Waes, V1
Bolaños-Guzmán, CA2
Li, Y2
Abdourahman, A1
Tamm, JA1
Pehrson, AL1
Sánchez, C2
Gulinello, M2
Olivares-Nazario, M2
Fernández-Guasti, A3
Martínez-Mota, L2
Rangaraju, S1
Solis, GM1
Andersson, SI1
Gomez-Amaro, RL1
Kardakaris, R1
Broaddus, CD1
Niculescu, AB1
Reyes, R2
Wolkers, CPB1
Serra, M1
Barbosa Júnior, A1
Urbinati, EC1
Mason, SS1
Baker, KB1
Davis, KW1
Pogorelov, VM1
Malbari, MM1
Ritter, R1
Wray, SP1
Gerhardt, B1
Lanthorn, TH1
Savelieva, KV1
Parise, EM1
Alcantara, LF1
Schuh, B1
Maffeo, ML1
Manojlovic, Z1
Couillard-Despres, S1
Wuertinger, C1
Kandasamy, M1
Caioni, M1
Stadler, K1
Aigner, R1
Bogdahn, U1
Aigner, L1
Hodes, GE1
Yang, L1
Van Kooy, J1
Santollo, J1
Shors, TJ1
Kobayashi, K1
Ikeda, Y1
Sakai, A1
Yamasaki, N1
Haneda, E1
Suzuki, H1
Duncan, MJ1
Hester, JM1
Hopper, JA1
Franklin, KM1
Isingrini, E1
Belzung, C1
d'Audiffret, A1
Camus, V1
Liu, JX1
Pinnock, SB1
Herbert, J2
Lee, LJ2
Capello, CF1
Ritchie, JC1
Stowe, ZN1
Newport, DJ1
Nemeroff, A1
Owens, MJ1
Récamier-Carballo, S1
Estrada-Camarena, E1
Doosti, MH1
Bakhtiari, A1
Zare, P1
Amani, M1
Majidi-Zolbanin, N1
Babri, S1
Salari, AA1
Yau, JL1
Hibberd, C1
Noble, J1
Seckl, JR1
O'Leary, KT1
Leslie, FM1
Shirokawa, T1
Ishida, Y1
Isobe, K1
Akhisaroglu, M1
Manev, R1
Akhisaroglu, E1
Uz, T1
Manev, H1
Kenis, G1
Bosmans, E1
Kajta, M1
Scharpe, S1
Maes, M1
Devanand, DP1
Nobler, MS1
Cheng, J1
Turret, N1
Pelton, GH1
Roose, SP1
Sackeim, HA1
Zhao, CS1
Puurunen, K1
Schallert, T1
Sivenius, J1
Jolkkonen, J1
Moore, TL1
Schettler, SP1
Killiany, RJ1
Herndon, JG1
Luebke, JI1
Moss, MB1
Rosene, DL1
Landry, M1
Frasier, M1
Chen, Z1
Van De Kar, LD1
Zhang, Y1
Garcia, F1
Battaglia, G1
Huang, GJ1
Kim, J1
Riggs, KW1
Misri, S1
Kent, N1
Oberlander, TF1
Grunau, RE1
Fitzgerald, C1
Rurak, DW1
Simonová, Z1
Dutt, J1
Chang, YC1
Tzeng, SF1
Yu, L1
Huang, AM1
Lee, HT1
Huang, CC1
Ho, CJ1
Shintani, N1
Hashimoto, H1
Tanaka, K1
Kawagishi, N1
Kawaguchi, C1
Hatanaka, M1
Ago, Y1
Matsuda, T1
Baba, A1
Lagace, DC1
Fischer, SJ1
Eisch, AJ1
Bian, X1
Patel, B1
Dai, X1
Galligan, JJ1
Swain, G1
Aguilar, E1
Ranchal, A1
Tena-Sempere, M1
Pinilla, L1
Akunne, HC1
Soliman, KF1
Altamura, AC1
Moro, AR1
Percudani, M1
Grilly, DM1
Pistell, PJ1
McReynolds, AM1
Meyer, JS1
Smith, JE1
Lakoski, JM1
Bastos, EF1
Marcelino, JL1
Amaral, AR1
Serfaty, CA1
Wegerer, V1
Moll, GH2
Bagli, M1
Rothenberger, A2
Rüther, E2
Huether, G2
Mehnert, C1
Wicker, M1
Bock, N1
Hansson, SR1
Hoffman, BJ1
Laudenslager, ML1
Clarke, AS1
Yoshimoto, K1
Kato, B1
Ueda, S1
Noritake, K1
Sakai, K1
Shibata, M1
Hori, M1
Kawano, H1
Takeuchi, Y1
Wakabayashi, Y1
Yasuhara, M1
Clineschmidt, BV1
Zacchei, AG1
Totaro, JA1
Pflueger, AB1
McGuffin, JC1
Wishousky, TI1
Morgan, WW1
Herbert, DC1
Khan, IA1
Thomas, P1
Tejani-Butt, SM1
Ordway, GA1
Alper, RH1
Bero, LA1
Kuhn, CM1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke[NCT03448159]Phase 252 participants (Actual)Interventional2019-01-01Completed
Perinatal Stress and Gene Influences: Pathways to Infant Vulnerability[NCT00525226]1,431 participants (Actual)Observational2007-09-30Completed
An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder[NCT01852383]Phase 430 participants (Actual)Interventional2006-01-31Completed
Cortex Motor Function Reorganization in Stroke Patients: A Longitudinal fMRI Study[NCT04794673]36 participants (Actual)Observational2020-01-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Cornell Dysthymia Rating Scale Scores From Week 0 to Week 12

Cornell Dysthymia Rating Scale scores from range 0-64. Lower or decreasing scores represent decreased severity and a better outcome, while higher or increasing scores represent more severe depression and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Week 0 and 12

Interventionunits on a scale (Mean)
Duloxetine28.8

Change in Hamilton Rating Scale for Depression (HAM-D, 24-item) From 0 Weeks to 12 Weeks.

The research rater completed the 24-item Hamilton Rating Scale for Depression (HAM-D) and documented the scores on each visit. Hamilton Rating Scale for Depression scores range from 0-50 with low scores or decreasing scores representing decreased severity and better outcome, and higher scores or increasing scores representing more severe depressive symptoms and a worse outcome. The change score was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: Screen (0) and 12 weeks

Interventionunits on a scale (Mean)
Duloxetine8

Change in the Treatment Emergent Symptom Scale (TESS) Total Score From Week 0 to Week 12.

The Treatment Emergent Symptom Scale (TESS) documents the presence of common side effects. There are 26 items and the total score range is 0-26. Low scores or decrease in scores represent less side effects and high scores or increase in scores represent more side effects. The change in side effect severity scores was calculated by subtracting the Week 12 score from the Week 0 score. (NCT01852383)
Timeframe: 0 and 12 weeks

Interventionunits on a scale (Mean)
Duloxetine5.2

Maximum Duloxetine Oral Dose

Maximum duloxetine oral dose (NCT01852383)
Timeframe: Week 0, 1, 2, 4, 6, 8, 10, 12

Interventionmg (Mean)
Duloxetine101

Reviews

3 reviews available for fluoxetine and Aging

ArticleYear
Neuroplasticity and behavioral effects of fluoxetine after experimental stroke.
    Restorative neurology and neuroscience, 2017, Volume: 35, Issue:5

    Topics: Aging; Animals; Brain; Fluoxetine; Humans; Neurogenesis; Neuronal Plasticity; Neurons; Selective Ser

2017
Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior.
    Progress in brain research, 2014, Volume: 211

    Topics: Aging; Animals; Behavior, Animal; Brain; Child; Disease Models, Animal; Fluoxetine; Humans; Methylph

2014
Clinical pharmacokinetics of fluoxetine.
    Clinical pharmacokinetics, 1994, Volume: 26, Issue:3

    Topics: Administration, Oral; Aged; Aging; Biological Availability; Dose-Response Relationship, Drug; Drug I

1994

Trials

3 trials available for fluoxetine and Aging

ArticleYear
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
    Aging, 2021, 10-05, Volume: 13, Issue:19

    Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Melli

2021
L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:10

    Topics: Acetylcarnitine; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cognitive Dysfunction; Diagn

2013
Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:1

    Topics: Age Factors; Aged; Aging; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method

2005

Other Studies

67 other studies available for fluoxetine and Aging

ArticleYear
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
    Nature, 2007, Nov-22, Volume: 450, Issue:7169

    Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevit

2007
Hippocampal BMP signaling as a common pathway for antidepressant action.
    Cellular and molecular life sciences : CMLS, 2021, Dec-22, Volume: 79, Issue:1

    Topics: Aging; Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Bone Morphogenetic Pro

2021
Involvement of chronic unpredictable mild stress-induced hippocampal LRP1 up-regulation in microtubule instability and depressive-like behavior in a depressive-like adult male rat model.
    Physiology & behavior, 2020, 03-01, Volume: 215

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Body Weight; Depression; Fluoxetine; Food

2020
Adolescent Fluoxetine Exposure Induces Persistent Gene Expression Changes in the Hippocampus of Adult Male C57BL/6 Mice.
    Molecular neurobiology, 2021, Volume: 58, Issue:4

    Topics: Aging; Animals; Fluoxetine; Gene Expression Regulation; Hippocampus; Insulin Receptor Substrate Prot

2021
Suppression of pro-inflammatory cytokine expression and lack of anti-depressant-like effect of fluoxetine in lipopolysaccharide-treated old female mice.
    International immunopharmacology, 2017, Volume: 48

    Topics: Aging; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Cytokines; Depres

2017
Behavioural outcomes of adult female offspring following maternal stress and perinatal fluoxetine exposure.
    Behavioural brain research, 2017, 07-28, Volume: 331

    Topics: Aging; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Female; Fluoxetine; Ma

2017
Chronic fluoxetine ameliorates adolescent chronic nicotine exposure-induced long-term adult deficits in trace conditioning.
    Neuropharmacology, 2017, Volume: 125

    Topics: Aging; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Conditioning, Psychological; Fear; Fluox

2017
Environmental enrichment accelerates ocular dominance plasticity in mouse visual cortex whereas transfer to standard cages resulted in a rapid loss of increased plasticity.
    PloS one, 2017, Volume: 12, Issue:10

    Topics: Aging; Animal Husbandry; Animals; Dominance, Ocular; Environment; Female; Fluoxetine; Mice; Mice, In

2017
Voluntary Exercise During Adolescence Mitigated Negative the Effects of Maternal Separation Stress on the Depressive-Like Behaviors of Adult Male Rats: Role of NMDA Receptors.
    Neurochemical research, 2018, Volume: 43, Issue:5

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Hippocampu

2018
Interneuron Simplification and Loss of Structural Plasticity As Markers of Aging-Related Functional Decline.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2018, 09-26, Volume: 38, Issue:39

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Dendrites; Evoked Potentials, Visual; Fluo

2018
Fluoxetine or Sox2 reactivate proliferation-defective stem and progenitor cells of the adult and aged dentate gyrus.
    Neuropharmacology, 2018, Volume: 141

    Topics: Aging; Animals; Cell Proliferation; Dentate Gyrus; Fluoxetine; Genetic Vectors; Lateral Ventricles;

2018
Fluoxetine exposure during pregnancy and lactation: Effects on acute stress response and behavior in the novelty-suppressed feeding are age and gender-dependent in rats.
    Behavioural brain research, 2013, Sep-01, Volume: 252

    Topics: Aging; Amygdala; Animals; Female; Fluoxetine; Lactation; Male; Paraventricular Hypothalamic Nucleus;

2013
Age-dependent role for Ras-GRF1 in the late stages of adult neurogenesis in the dentate gyrus.
    Hippocampus, 2014, Volume: 24, Issue:3

    Topics: Aging; Animals; Animals, Newborn; Animals, Suckling; Cell Division; Cell Survival; Dentate Gyrus; Di

2014
Chronic fluoxetine treatment reduces parvalbumin expression and perineuronal nets in gamma-aminobutyric acidergic interneurons of the frontal cortex in adult mice.
    Molecular brain, 2013, Nov-05, Volume: 6

    Topics: Aging; Animals; Apoptosis; CA3 Region, Hippocampal; Calbindin 2; Cell Count; Fluoxetine; Frontal Lob

2013
Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:9

    Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Anxiety Disorders; Butyr

2014
SSRI or CRF antagonism partially ameliorate depressive-like behavior after adolescent social defeat.
    Behavioural brain research, 2014, Aug-15, Volume: 270

    Topics: Aging; Animals; Behavior, Animal; Depression; Fluoxetine; Male; Methylcellulose; Rats; Rats, Wistar;

2014
Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice.
    Pharmacology, biochemistry, and behavior, 2015, Volume: 135

    Topics: Aging; Animals; Antidepressive Agents; Cell Proliferation; Cognition Disorders; Female; Fluoxetine;

2015
Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test.
    Behavioural pharmacology, 2016, Volume: 27, Issue:1

    Topics: Aging; Animals; Antidepressive Agents; Depressive Disorder; Desipramine; Disease Models, Animal; Dos

2016
Atypical antidepressants extend lifespan of Caenorhabditis elegans by activation of a non-cell-autonomous stress response.
    Aging cell, 2015, Volume: 14, Issue:6

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Caenorhabditis elegans; Caenorhabditis ele

2015
Sex and age differences in the antidepressant-like effect of fluoxetine in the forced swim test.
    Pharmacology, biochemistry, and behavior, 2017, Volume: 152

    Topics: Aging; Animals; Antidepressive Agents; Dose-Response Relationship, Drug; Estrous Cycle; Female; Fluo

2017
Acute fluoxetine treatment increases aggressiveness in juvenile matrinxã (Brycon amazonicus).
    Fish physiology and biochemistry, 2017, Volume: 43, Issue:3

    Topics: Aggression; Aging; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Characiforme

2017
Distinct Antidepressant-Like and Cognitive Effects of Antidepressants with Different Mechanisms of Action in Middle-Aged Female Mice.
    The international journal of neuropsychopharmacology, 2017, 06-01, Volume: 20, Issue:6

    Topics: Aging; Animals; Antidepressive Agents; Cognition; Cohort Studies; Depression; Duloxetine Hydrochlori

2017
Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
    European journal of pharmacology, 2009, Jan-14, Volume: 602, Issue:2-3

    Topics: Aging; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Fluoxetine; Hindlimb Suspension;

2009
Nicotine exposure during adolescence induces a depression-like state in adulthood.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:6

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De

2009
Ageing abolishes the effects of fluoxetine on neurogenesis.
    Molecular psychiatry, 2009, Volume: 14, Issue:9

    Topics: Age Factors; Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Brain; Brom

2009
Prozac during puberty: distinctive effects on neurogenesis as a function of age and sex.
    Neuroscience, 2009, Oct-06, Volume: 163, Issue:2

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Bromodeoxyuridine; Cell Proliferation; Cel

2009
Reversal of hippocampal neuronal maturation by serotonergic antidepressants.
    Proceedings of the National Academy of Sciences of the United States of America, 2010, May-04, Volume: 107, Issue:18

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Biomarkers; Calbindins; Down-Regulation; F

2010
The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors.
    The European journal of neuroscience, 2010, Volume: 31, Issue:9

    Topics: Aging; Animals; Circadian Rhythm; Cricetinae; Fluoxetine; Gastrin-Releasing Peptide; Male; Motor Act

2010
Chronic treatment with fluoxetine for more than 6 weeks decreases neurogenesis in the subventricular zone of adult mice.
    Molecular brain, 2011, Mar-08, Volume: 4

    Topics: Aging; Animals; Bromodeoxyuridine; Calbindins; Cell Count; Cell Proliferation; Cerebral Ventricles;

2011
Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2011, Volume: 19, Issue:4

    Topics: Aging; Animals; Biomarkers; Body Weight; Depression; Disease Models, Animal; Fluoxetine; Grooming; H

2011
Novel control by the CA3 region of the hippocampus on neurogenesis in the dentate gyrus of the adult rat.
    PloS one, 2011, Mar-18, Volume: 6, Issue:3

    Topics: Aging; Animals; Bromodeoxyuridine; CA3 Region, Hippocampal; Calbindins; Cell Count; Cell Proliferati

2011
Neonatal fluoxetine exposure alters motor performances of adolescent rats.
    Developmental neurobiology, 2012, Volume: 72, Issue:8

    Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Fluoxetine; Male; Motor

2012
Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 339, Issue:1

    Topics: Aging; Animals; Anxiety; Brain; Central Nervous System; Female; Fetus; Fluoxetine; Image Processing,

2011
Synergistic effect of estradiol and fluoxetine in young adult and middle-aged female rats in two models of experimental depression.
    Behavioural brain research, 2012, Aug-01, Volume: 233, Issue:2

    Topics: Aging; Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Depression; Disease

2012
Impacts of early intervention with fluoxetine following early neonatal immune activation on depression-like behaviors and body weight in mice.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Jun-03, Volume: 43

    Topics: Aging; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Behavior, Animal; Body W

2013
The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats.
    Brain research. Molecular brain research, 2002, Oct-15, Volume: 106, Issue:1-2

    Topics: Aging; Animals; Brain; Fluoxetine; In Situ Hybridization; Male; Maze Learning; Memory; Rats; Rats, I

2002
Developmental regulation of nicotinic acetylcholine receptor-mediated [3H]norepinephrine release from rat cerebellum.
    Journal of neurochemistry, 2003, Volume: 84, Issue:5

    Topics: Age Factors; Aging; Animals; Animals, Newborn; Cerebellum; Dose-Response Relationship, Drug; Female;

2003
Age-related changes in the release and uptake activity of presynaptic axon terminals of rat locus coeruleus neurons.
    Neuroscience letters, 2003, Jul-03, Volume: 344, Issue:3

    Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aging; Animals; Clonidine; Fluoxetine; Fron

2003
Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus.
    Neuroreport, 2003, Aug-06, Volume: 14, Issue:11

    Topics: Aging; Animals; Blotting, Western; Fluoxetine; Hippocampus; Immunoassay; Injections, Intraperitoneal

2003
Stimulatory effect of antidepressants on the production of IL-6.
    International immunopharmacology, 2004, Volume: 4, Issue:2

    Topics: 5-Hydroxytryptophan; Adult; Age Factors; Aging; Antidepressive Agents; Blood Cells; Cyclohexanols; D

2004
Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury.
    Behavioural brain research, 2005, Mar-30, Volume: 158, Issue:2

    Topics: Affect; Aggression; Aging; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; B

2005
Cognitive impairment in aged rhesus monkeys associated with monoamine receptors in the prefrontal cortex.
    Behavioural brain research, 2005, May-28, Volume: 160, Issue:2

    Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Age Factors; Aging; Analysis of Variance; A

2005
Fluoxetine treatment of prepubescent rats produces a selective functional reduction in the 5-HT2A receptor-mediated stimulation of oxytocin.
    Synapse (New York, N.Y.), 2005, Volume: 58, Issue:2

    Topics: Adrenocorticotropic Hormone; Aging; Animals; Body Weight; Brain; Corticosterone; Dose-Response Relat

2005
Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone.
    Biological psychiatry, 2006, Apr-01, Volume: 59, Issue:7

    Topics: Age Factors; Aging; Animals; Cell Proliferation; Corticosterone; Dentate Gyrus; Depressive Disorder,

2006
Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.
    British journal of clinical pharmacology, 2006, Volume: 61, Issue:2

    Topics: Adult; Aging; Antidepressive Agents, Second-Generation; Breast Feeding; Depressive Disorder, Major;

2006
Are both embryonic migratory pathways preserved in the adult brain cerebral cortex?
    Prague medical report, 2006, Volume: 107, Issue:1

    Topics: Aging; Animals; Cell Differentiation; Cell Movement; Cell Proliferation; Cerebral Cortex; Fluoxetine

2006
Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups.
    Neurobiology of disease, 2006, Volume: 24, Issue:1

    Topics: Aging; Animals; Animals, Newborn; Antimetabolites; Blotting, Western; Brain-Derived Neurotrophic Fac

2006
Serotonergic inhibition of intense jumping behavior in mice lacking PACAP (Adcyap1-/-).
    Annals of the New York Academy of Sciences, 2006, Volume: 1070

    Topics: 5-Hydroxytryptophan; Aging; Animals; Behavior, Animal; Fluoxetine; Mice; Mice, Knockout; Physical Co

2006
Gender and endogenous levels of estradiol do not influence adult hippocampal neurogenesis in mice.
    Hippocampus, 2007, Volume: 17, Issue:3

    Topics: Aging; Animals; Bromodeoxyuridine; Cell Differentiation; Cell Proliferation; Estradiol; Estrous Cycl

2007
High mucosal serotonin availability in neonatal guinea pig ileum is associated with low serotonin transporter expression.
    Gastroenterology, 2007, Volume: 132, Issue:7

    Topics: Aging; Animals; Animals, Newborn; Calcium; Electrophysiology; Fluoxetine; Guinea Pigs; Hydroxyindole

2007
Serotoninergic control of prolactin secretion in prepubertal male rats.
    European journal of endocrinology, 1994, Volume: 131, Issue:5

    Topics: 5-Hydroxytryptophan; Aging; Androstane-3,17-diol; Animals; Fluoxetine; Hydroxyindoleacetic Acid; Mal

1994
Serotonin modulation of pain responsiveness in the aged rat.
    Pharmacology, biochemistry, and behavior, 1994, Volume: 48, Issue:2

    Topics: Aging; Animals; Drug Synergism; Fluoxetine; Male; Methysergide; Morphine; Pain; Pain Measurement; Ra

1994
Fluoxetine alters the effects of cocaine on vigilance task performance of rats.
    Pharmacology, biochemistry, and behavior, 1997, Volume: 56, Issue:3

    Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Arousal; Cocaine; Discrimination Learning;

1997
Effects of prenatal cocaine exposure on serotonin and norepinephrine transporter density in the rat brain.
    Annals of the New York Academy of Sciences, 1998, Jun-21, Volume: 846

    Topics: Aging; Animals; Brain; Carrier Proteins; Cocaine; Female; Fluoxetine; Male; Membrane Glycoproteins;

1998
Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus.
    Synapse (New York, N.Y.), 1998, Volume: 30, Issue:3

    Topics: Aging; Animals; Antidepressive Agents; Drug Administration Schedule; Duloxetine Hydrochloride; Elect

1998
Fluoxetine-induced plasticity in the rodent visual system.
    Brain research, 1999, Apr-03, Volume: 824, Issue:1

    Topics: Aging; Animals; Axons; Fluoxetine; Neuronal Plasticity; Rats; Rats, Inbred Strains; Retina; Selectiv

1999
Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life.
    Journal of child and adolescent psychopharmacology, 1999, Volume: 9, Issue:1

    Topics: Aging; Animals; Behavior, Animal; Brain Chemistry; Carrier Proteins; Fluoxetine; Growth; Membrane Gl

1999
Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood.
    Brain research. Developmental brain research, 2000, Feb-07, Volume: 119, Issue:2

    Topics: Aging; Animals; Brain; Brain Stem; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane Trans

2000
Transient expression of a functional serotonin transporter in Merkel cells during late gestation and early postnatal rat development.
    Experimental brain research, 2000, Volume: 130, Issue:3

    Topics: Aging; Animals; Carrier Proteins; Cells, Cultured; Embryonic and Fetal Development; Fluoxetine; Gene

2000
Antidepressant treatment during social challenge prior to 1 year of age affects immune and endocrine responses in adult macaques.
    Psychiatry research, 2000, Jul-24, Volume: 95, Issue:1

    Topics: Adolescent; Adrenergic Uptake Inhibitors; Aging; Animals; Antibody Formation; Antidepressive Agents,

2000
Dopamine and serotonin uptake inhibitors on the release of dopamine and serotonin in the nucleus accumbens of young and aged rats.
    Mechanisms of ageing and development, 2001, Volume: 122, Issue:15

    Topics: Aging; Animals; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Fluoxetine; Male; Neurons; Nucleus Ac

2001
Fenfluramine and brain serotonin.
    Annals of the New York Academy of Sciences, 1978, Jun-12, Volume: 305

    Topics: 5-Hydroxytryptophan; Aging; Animals; Animals, Newborn; Brain; Dealkylation; Dihydroxyphenylalanine;

1978
Elevation of serum prolactin levels after the inhibition of serotonin uptake.
    Endocrinology, 1978, Volume: 103, Issue:4

    Topics: Aging; Animals; Diencephalon; Fluoxetine; Hydroxyindoleacetic Acid; Male; Methysergide; Prolactin; P

1978
Stimulatory effects of serotonin on maturational gonadotropin release in the Atlantic croaker, Micropogonias undulatus.
    General and comparative endocrinology, 1992, Volume: 88, Issue:3

    Topics: Aging; Animals; Female; Fluoxetine; Gonadotropin-Releasing Hormone; Gonadotropins; In Vitro Techniqu

1992
Effect of age on [3H]nisoxetine binding to uptake sites for norepinephrine in the locus coeruleus of humans.
    Brain research, 1992, Jun-26, Volume: 583, Issue:1-2

    Topics: Adult; Aged; Aging; Autoradiography; Biological Transport; Female; Fluoxetine; Humans; Locus Coerule

1992
Effects of the selective serotonin reuptake inhibitor fluoxetine on baroreceptor reflex sensitivity and body weight in young and old rats.
    Journal of gerontology, 1992, Volume: 47, Issue:4

    Topics: Aging; Animals; Blood Pressure; Body Weight; Fluoxetine; Heart Rate; Male; Nitroglycerin; Phenylephr

1992
Differential ontogeny of opioid, dopaminergic and serotonergic regulation of prolactin secretion.
    The Journal of pharmacology and experimental therapeutics, 1987, Volume: 240, Issue:3

    Topics: 5-Hydroxytryptophan; Aging; Animals; Animals, Newborn; Corticosterone; Cyproheptadine; Fluoxetine; G

1987